La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Shionogi Crescita futura

Future criteri di controllo 1/6

Shionogi prevede che gli utili e i ricavi cresceranno rispettivamente di 0.2% e 2.1% all'anno. Si prevede che l'EPS crescerà di 2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 10.9% in 3 anni.

Informazioni chiave

0.4%

Tasso di crescita degli utili

2.2%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	13.8%
Tasso di crescita dei ricavi	2.0%
Rendimento futuro del capitale proprio	10.9%
Copertura analitica	Good
Ultimo aggiornamento	27 Sep 2024

Aggiornamenti recenti sulla crescita futura

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

Jul 31

Recent updates

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

Jul 31

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Jul 26

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Jul 11

Shionogi's (TSE:4507) Soft Earnings Don't Show The Whole Picture

Jun 28

Is Shionogi & Co., Ltd. (TSE:4507) Trading At A 28% Discount?

May 07

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon

Mar 22

Shionogi (TSE:4507) Will Pay A Dividend Of ¥75.00

Mar 01

Previsioni di crescita degli utili e dei ricavi

TSE:4507 - Stime future degli analisti e dati finanziari passati (JPY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	466,550	167,866	171,428	198,441	12
3/31/2026	451,287	159,507	163,738	184,128	13
3/31/2025	436,331	159,510	171,086	195,192	13
6/30/2024	423,356	150,105	102,435	156,400	N/A
3/31/2024	435,081	162,030	126,017	154,284	N/A
12/31/2023	425,157	154,458	104,561	128,536	N/A
9/30/2023	506,446	218,294	147,126	165,030	N/A
6/30/2023	464,156	192,805	145,825	171,002	N/A
3/31/2023	426,684	184,965	140,680	177,867	N/A
12/31/2022	453,859	200,914	97,163	141,746	N/A
9/30/2022	340,832	118,318	51,961	105,430	N/A
6/30/2022	338,012	116,669	72,156	120,051	N/A
3/31/2022	335,138	114,185	70,504	102,068	N/A
12/31/2021	292,384	96,785	87,101	127,108	N/A
9/30/2021	293,810	115,608	82,351	117,069	N/A
6/30/2021	294,740	122,560	83,364	115,020	N/A
3/31/2021	297,177	111,858	76,095	109,039	N/A
12/31/2020	304,276	117,422	N/A	N/A	N/A
9/30/2020	320,946	119,958	105,372	117,777	N/A
6/30/2020	325,548	119,311	N/A	N/A	N/A
3/31/2020	333,371	122,193	120,172	131,940	N/A
12/31/2019	351,993	129,259	N/A	N/A	N/A
9/30/2019	356,395	126,479	127,199	138,629	N/A
6/30/2019	354,422	125,285	N/A	N/A	N/A
3/31/2019	363,721	132,759	136,560	145,684	N/A
12/31/2018	346,547	123,483	N/A	N/A	N/A
9/30/2018	340,698	116,426	147,122	155,169	N/A
6/30/2018	358,168	124,748	N/A	N/A	N/A
3/31/2018	344,667	108,866	N/A	129,790	N/A
12/31/2017	345,719	96,065	N/A	N/A	N/A
9/30/2017	355,961	103,017	N/A	109,944	N/A
6/30/2017	340,755	87,353	N/A	N/A	N/A
3/31/2017	338,890	83,879	N/A	111,903	N/A
12/31/2016	340,583	92,559	N/A	N/A	N/A
9/30/2016	326,795	76,499	N/A	105,915	N/A
6/30/2016	319,268	69,566	N/A	N/A	N/A
3/31/2016	309,973	66,687	N/A	102,290	N/A
12/31/2015	299,645	59,468	N/A	N/A	N/A
9/30/2015	282,428	55,736	N/A	64,409	N/A
6/30/2015	275,117	43,395	N/A	N/A	N/A
3/31/2015	273,991	44,060	N/A	45,604	N/A
12/31/2014	271,887	30,857	N/A	N/A	N/A
9/30/2014	280,844	30,136	N/A	61,135	N/A
6/30/2014	285,189	41,307	N/A	N/A	N/A
3/31/2014	289,717	41,831	N/A	79,496	N/A
12/31/2013	289,559	75,622	N/A	N/A	N/A
9/30/2013	284,296	73,269	N/A	67,008	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 4507 ( 0.4% all'anno) è superiore al tasso di risparmio ( 0.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 4507 ( 0.2% all'anno) cresceranno più lentamente rispetto al mercato JP ( 8.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 4507 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 4507 ( 2.1% all'anno) crescerà più lentamente rispetto al mercato JP ( 4.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4507 ( 2.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 4507 sarà basso tra 3 anni ( 10.9 %).

Shionogi Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for First Half of the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Full Year Ending March 31, 2023

Consensus EPS estimates fall by 14%

Shionogi & Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022

Recent updates

Shionogi & Co., Ltd. Submits New Drug Application in Japan for Zuranolone as A Treatment for Major Depressive Disorder

New minor risk - Dividend sustainability

Upcoming dividend of JP¥85.00 per share

Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Shionogi & Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Shionogi & Co., Ltd. to Report Q2, 2025 Results on Oct 28, 2024

Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Final dividend of JP¥85.00 announced

Shionogi's (TSE:4507) Soft Earnings Don't Show The Whole Picture

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

Shionogi & Co., Ltd. to Report Q1, 2025 Results on Jul 29, 2024

Investor sentiment deteriorates as stock falls 15%

Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024

Now 21% undervalued

Is Shionogi & Co., Ltd. (TSE:4507) Trading At A 28% Discount?

Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study (PERSEUS) of Fetroja®/F etcroja® (cefiderocol)

Shionogi & Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon

Upcoming dividend of JP¥75.00 per share

Now 20% undervalued

Shionogi (TSE:4507) Will Pay A Dividend Of ¥75.00

Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan

Now 21% undervalued after recent price drop

Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shionogi & Co., Ltd Announces the Launch of Fetroja(Cefiderocol) Intravenous Infusion 1g Vial in Japan on December 20, 2023

Shionogi & Co., Ltd. Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023

Shionogi & Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Shionogi & Co., Ltd. Presents New Real-World Evidence Demonstrating Effectiveness of Early Treatment with Fetroja®? (Cefiderocol) in Appropriate Patients

Now 21% undervalued

Upcoming dividend of JP¥75.00 per share at 2.3% yield

Shionogi & Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shionogi & Co., Ltd. (TSE:4507) announces an Equity Buyback for 12,500,000 shares, representing 4.2% for ¥7,500 million.

Insufficient new directors

Eddingpharm Announces Approval of Mulpleta®? (Lusutrombopag) in China

Shionogi & Co., Ltd. Announces Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19

Full year 2023 earnings: EPS exceeds analyst expectations

Now 20% undervalued

Shionogi & Co., Ltd. Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shionogi & Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Shionogi & Co., Ltd. Announces Year-End Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023; Provides Dividend Guidance for the End of Second Quarter of Fiscal Year 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥60.00 per share at 2.0% yield

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Availability of Innovative Antibiotic, Cefiderocol in Norway

Shionogi & Co., Ltd. Announces Initiation of Phase1/2/3 Clinical Trial (Part 2), Phase 3 Additional Dose Clinical Trial in Japanese Pediatric of the COVID-19 Vaccine, S-268019

Shionogi & Co., Ltd. to Report Q3, 2023 Results on Jan 30, 2023

Shionogi & Co., Ltd. Files for Approval of S-268019, A COVID-19 Recombinant Protein-Based Vaccine, in Japan

Shionogi & Co., Ltd. Announces Tablets 125Mg Approved in Japan for the Treatment of SARS-CoV-2 Infection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2022, Payable on December 1, 2022

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for First Half of the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Achievement of the Primary Endpoint for Ensitrelvir (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia

Upcoming dividend of JP¥60.00 per share

Shionogi & Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Shionogi & Co., Ltd Announces Ensitrelvir Fumaric Acid (S-217622), Therapeutic Drug for COVID-19,Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75